If you don't know your blood type, you're not alone. However it is important medical information to know, and here's how you ...

Legendary actor and filmmaker Mel Gibson revealed this week that he couldn't walk for months after taking the COVID vaccine.

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, ...

Five years after the first cases of COVID-19, reports of hMPV, an obscure respiratory virus in China may understandably raise ...

Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day.

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in ...

CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investors Proceeds will be used to support the advancement of multiple first-in-class and ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

Professor Jae-Byum Chang and Professor Yeon Sik Jung's joint research team of the Department of Materials Science and ...

Respiratory illnesses are on the rise across San Antonio, Bexar County and Texas. Doctor Jason Bowling, a professor and infectious diseases specialist at UT Health San Antonio and the Chief ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...